New hope for GIST patients: oral paclitaxel targets Drug-Resistant tumors

NCT ID NCT06326346

First seen Apr 13, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This study tests an oral form of paclitaxel (Liporaxel) in 28 adults with advanced gastrointestinal stromal tumors (GIST) that no longer respond to three standard treatments. The goal is to see if the drug can control tumor growth for at least 16 weeks. Participants must have low levels of a protein called P-glycoprotein, which may make the treatment more effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center, University of Ulsan College of Medicine

    RECRUITING

    Seoul, Songpagu, 138-736, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.